Full-Time

Senior Computational Geneticist

Multiple Teams

Posted on 8/12/2026

Deadline 8/19/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$106k - $176.6k/yr

+ 15% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Cambridge, MA, USA

Hybrid

Hybrid role requiring on-site work an average of 2.5 days per week; relocation support may be available.

PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Python
R
SQL
Machine Learning
Perl
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A PhD and post-doctoral experience in genetics, statistical genetics, or genetic epidemiology with two years of relevant experience are required.
  • Strong statistical and quantitative skills, including knowledge of epidemiological principles and population-based research, are required.
  • Experience managing large projects, collaborations, or consortia is required.
  • Demonstrated experience using generative artificial intelligence tools such as Microsoft Copilot, ChatGPT, Claude, or Gemini to support scientific research, knowledge synthesis, data interpretation, or analytical workflows is required.
  • Understanding of the capabilities, limitations, sources of bias, and appropriate application of large language models and other artificial intelligence technologies in biomedical research is required.
  • Ability to incorporate artificial intelligence-assisted approaches into scientific workflows while maintaining sound scientific judgment and critically evaluating results is required.
  • Experience analyzing genetic datasets and integrating additional data types to advance clinical and biological understanding is required.
  • Proficiency in programming, scripting, querying, or statistical analysis languages such as R, Python, Perl, or SQL is required.
  • Familiarity with genetics platforms is required.
  • Ability to interact and communicate effectively with multidisciplinary scientists, researchers, and non-scientists internally and externally is required.
  • Ability to perform complex statistical analysis is required.
Responsibilities
  • Provide quantitative genetics expertise and conduct analyses through interactions with biologists within the Internal Medicine Research Unit.
  • Apply genetics and functional genomics to identify novel therapeutic targets, review and validate therapeutic hypotheses, understand disease pathogenesis and causal pathways, identify mechanism-related biomarkers by integrating genetics with clinical and omics datasets, identify potential disease indications, and match novel therapies to patients with relevant disease subtypes.
  • Ensure high-quality genetic and omics data are incorporated into exploratory research by interacting with internal partners in statistics, bioinformatics, computational biology, clinical science, and project leadership.
  • Partner with artificial intelligence and machine learning scientists to identify opportunities where artificial intelligence-enabled approaches can enhance genetics-driven target discovery, causal inference, biological interpretation, biomarker identification, and patient stratification.
  • Collaborate with research biologists and project teams to translate genetic and related data into portfolio asset prioritization, and collaborate with clinical teams on patient selection, stratification, and trial design.
  • Evaluate and incorporate artificial intelligence-assisted approaches into genetics research workflows, including literature synthesis, knowledge discovery, biological interpretation, hypothesis generation, and integration of large-scale human genetics and multi-omics datasets.
  • Manage, develop, and maintain internal and external collaborative projects according to specified timelines and milestones.
  • Communicate study findings and analyses to internal partners, leadership, administration, and collaborators.
  • Manage, support, and promote relationships with the external community to add value to target selection and validation.
Desired Qualifications
  • Background in human biology or medicine, with knowledge of disease pathophysiology for metabolic disease.
  • Track record of innovative and impactful research in the genetics of complex traits, including peer-reviewed publications.
  • Experience applying large language models and artificial intelligence-enabled tools to scientific discovery, biological interpretation, literature review, knowledge extraction, or hypothesis generation.
  • Ability to identify opportunities where artificial intelligence can enhance scientific productivity and decision-making while recognizing when human expertise, experimental validation, or additional evidence is required.
  • Scientific leadership experience with responsibility for research project delivery.
  • Experience with at least one additional omics technology, such as metabolomics, lipidomics, transcriptomics, or epigenetics.
  • Ability to identify, propose, and develop new analytical concepts.
  • Ability to lead and support teams, multitask, prioritize competing time-sensitive projects, and work effectively in a multidisciplinary matrix research team.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pfizer raised 2026 revenue guidance to $60.5-$62.5 billion on August 4, 2026.
  • Non-COVID revenue grew 5% operationally in Q2 2026, showing durable post-pandemic execution.
  • Padcev gained a new bladder-cancer approval in July 2026, expanding oncology share and pricing power.

What critics are saying

  • Eliquis faces U.S. loss of exclusivity around 2027, threatening Pfizer's biggest cash engine.
  • Pfizer cut Oxbryta after July 2026 FDA talks, proving clinical failures still destroy value.
  • Patented COVID revenue keeps collapsing; Paxlovid fell 95% in Q2 2026, removing pandemic support.

What makes Pfizer unique

  • Pfizer's global scale and regulatory reach still converts R&D into worldwide launches quickly.
  • Padcev, Vyndaqel, and Lorbrena diversified growth beyond Comirnaty and Paxlovid in Q2 2026.
  • PREVNAR 20 won Québec funding in July 2026, reinforcing Pfizer's vaccine distribution moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.

Yahoo Finance
Aug 18th, 2026
Two profitable stocks with solid fundamentals and one to ignore

Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.

Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

INACTIVE